Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Wang JM, Singh C, Liu L, Irwin RW, Chen S, Chung EJ, Thompson RF, Brinton RD. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6498-503. PubMed Abstract

  
Comments on Paper and Primary News
  Comment by:  Roberta Diaz Brinton, ARF Advisor
Submitted 23 March 2010  |  Permalink Posted 23 March 2010
  I recommend this paper

I suggest reading the excellent Alzforum news article by Tom Fagan on our findings regarding the efficacy of allopregnanolone to reverse neurogenic and cognitive deficits in the 3xTgAD male mouse in PNAS and hyperphosphorylated tau in neural progenitor cells reported by Orly Lazarov and colleagues.

View all comments by Roberta Diaz Brinton

  Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice

Comment by:  Felix Hernandez
Submitted 23 March 2010  |  Permalink Posted 23 March 2010

We have previously published that doublecortin positive cells also express hyperphosphorylated tau (Fuster-Matanzo et al., 2009). Thus, we demonstrated that new neurons generated in the subgranular zone express tau in a hyperphosphorylated form. Phospho-tau expression colocalized with doublecortin but not with glial fibrillary acidic protein, Ki67 or calbindin. The same was observed in the subventricular zone. Tau knockout mice did not show a significant decrease in the number of doublecortin-positive cells, although a deficit in migration was observed. These findings suggest that tau phosphorylation in doublecortin-positive cells is involved in normal migration of new neurons.

References:
Fuster-Matanzo A, de Barreda EG, Dawson HN, Vitek MP, Avila J, Hernández F. Function of tau protein in adult newborn neurons. FEBS Lett. 2009 583(18):3063-8. Abstract

View all comments by Felix Hernandez

  Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice

Comment by:  J. Lucy Boyd
Submitted 24 March 2010  |  Permalink Posted 24 March 2010
  I recommend this paper

  Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice

Comment by:  Thomas Bayer, Oliver Wirths
Submitted 8 April 2010  |  Permalink Posted 8 April 2010

Whether or not physical activity and/or enriched environment could have a potential therapeutic effect in patients with Alzheimer disease (AD) is usually assessed in transgenic mouse models. There is no doubt that in wild-type mice, both physical activity and enriched environment lead to increased neurogenesis in some brain areas, e.g., the dentate gyrus. In contrast, the situation is much less clear in APP transgenic mouse models.

In a recent study, we analyzed neurogenesis in APP/PS1KI mice and quantified the number of doublecortin (DCX)-positive neurons in the subgranular zone of the dentate gyrus (Cotel et al., 2010). Already at the age of two months, a significantly reduced number of DCX-positive neurons were detected in APP/PS1KI mice compared to age-matched wild-type mice. This is the time point when the first amyloid plaques become apparent. In good agreement with a previous study (Faure et al., 2009), neurogenesis was almost completely absent by the age of six months. Interestingly, this loss of neurogenesis could not be modified by keeping the mice in an enriched...  Read more

  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:
Immunohistochemistry: Brain sections were incubated with monoclonal anti-BrdU (Novus). For identifying the phenotype of the newly formed BrdU-positive cells, adjacent sections were incubated overnight with the following primary antibodies: rat monoclonal anti-BrdU (BU1/75) (AdB Serotec), rabbit anti-GFAP (DAKO), mouse monoclonal anti-NeuN (A60) (Chemicon MIllipore), goat anti-Doublecortin (Santa Cruz Biotechnology). For evaluating AD pathology development, sections were incubated with mouse monoclonal anti-Amyloid beta (6E10) (Signet Covance).
Western Blot: Protein extracts from mouse hippocampus and cortex were separated by SDS gel. After transfer, PVDF membrane was plotted with mouse monoclonal anti-proliferating cell nuclear antigen PCNA (PC10) (Zymed Invitrogen), rabbit anti-CDC2/p34 (Novus Biologicals), mouse monoclonal anti-Amyloid beta (6E10) (Signet), rabbit anti-Amyloid beta 1-42 (Chemicon Millipore), mouse monoclonal anti-human tau PHF (AT8) (Pierce Thermo Scientific) and mouse monoclonal anti-human tau PHF (HT7) (Pierce Thermo Scientific).

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad